Sci-Tech News Today
SEE OTHER BRANDS

The latest news on science and technology

Sci-Tech News Today: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Sci-Tech News Today.

Press releases published on August 8, 2025

DIH Appoints Scott R. Burell to DIH Holding US, Inc. Board of Directors

DIH Appoints Scott R. Burell to DIH Holding US, Inc. Board of Directors

NORWELL, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- DIH Holding US, Inc. ("DIH")(NASDAQ:DHAI), a global provider of advanced robotic devices used in rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and …

Vaxart CEO Issues Letter to Stockholders

Vaxart CEO Issues Letter to Stockholders

- Management Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on September 4, 2025 - SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical- …

Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients

Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients

TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, …

Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea

Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea

MELBOURNE, Australia and NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage pharmaceutical company developing innovative combination therapies for prevalent medical conditions, today announced new patient- …

MAX Power Closes Financings for $4.45 Million with Eric Sprott as Lead Order

MAX Power Closes Financings for $4.45 Million with Eric Sprott as Lead Order

VANCOUVER, British Columbia, Aug. 08, 2025 (GLOBE NEWSWIRE) -- MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) (“MAX Power” or the “Company”) is pleased to announce that in conjunction with the previously announced closings of its non- …

Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma

Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma

SHANGHAI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel …

Silicon Motion to Attend Upcoming Investor Conferences

Silicon Motion to Attend Upcoming Investor Conferences

TAIPEI, Taiwan and MILPITAS, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Silicon Motion Technology Corporation (NasdaqGS: SIMO), a global leader in designing and marketing NAND flash controllers for solid state storage devices, today announced that it will …

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes

– 94% reduction in HSV-2 shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed in cohort evaluating 350 mg weekly oral dose compared to placebo over 29-day evaluation period – – 94% reduction in genital …

Boralex reports second quarter operating income comparable to 2024 and actively pursue its development and construction activities

Boralex reports second quarter operating income comparable to 2024 and actively pursue its development and construction activities

MONTREAL, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Boralex Inc. (“Boralex” or the “Corporation”) (TSX: BLX) is pleased to report its results for the second quarter of 2025. Highlights Financial results Lower EBITDA(A)1, operating income and net earnings in Q2- …

Boralex annonce un résultat d'exploitation du deuxième trimestre comparable à celui de 2024 et poursuit activement ses activités de développement et de construction de projets

Boralex annonce un résultat d'exploitation du deuxième trimestre comparable à celui de 2024 et poursuit activement ses activités de développement et de construction de projets

MONTRÉAL, 08 août 2025 (GLOBE NEWSWIRE) -- Boralex inc. (« Boralex » ou la « Société ») (TSX : BLX) annonce ses résultats pour le deuxième trimestre de l'exercice 2025. Faits saillants Résultats financiers BAIIA(A) 1, résultat d'exploitation et résultat …

Boralex annonce la nomination d’André Courville à titre de président du conseil d’administration

Boralex annonce la nomination d’André Courville à titre de président du conseil d’administration

MONTRÉAL, 08 août 2025 (GLOBE NEWSWIRE) -- Boralex inc. (« Boralex » ou la « Société ») (TSX : BLX) annonce la nomination de M. André Courville à titre de Président du Conseil d’administration. Il succèdera ainsi le 30 septembre prochain à M. Alain Rhéaume …

Boralex announces the appointment of André Courville as Chair of the Board of Directors

Boralex announces the appointment of André Courville as Chair of the Board of Directors

MONTREAL, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Boralex Inc. (“Boralex” or the “Company”) (TSX: BLX) announces the appointment of Mr. André Courville as Chair of the Board of Directors. He will officially succeed Mr. Alain Rhéaume on September 30, following Mr …

Boralex announces the departure of its Chief Financial Officer

Boralex announces the departure of its Chief Financial Officer

MONTREAL, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Boralex Inc. (“Boralex” or the “Company”) (TSX: BLX) announces that Bruno Guilmette, Executive Vice President and Chief Financial Officer, has chosen to take on new challenges by accepting a new professional …

Boralex annonce le départ de son chef de la direction financière

Boralex annonce le départ de son chef de la direction financière

MONTRÉAL, 08 août 2025 (GLOBE NEWSWIRE) -- Boralex inc. (« Boralex » ou la « Société ») (TSX : BLX) annonce que Bruno Guilmette, Premier vice-président et chef de la direction financière, a choisi de relever de nouveaux défis en saisissant une nouvelle …

Leanova UK offers Evidence-Based Weight Management in the United Kingdom market

Leanova UK offers Evidence-Based Weight Management in the United Kingdom market

London, UK, Aug. 08, 2025 (GLOBE NEWSWIRE) --  Leanova, a Dutch-owned health supplement company has entered the United Kingdom with its core product, a plant-based weight loss supplement. Designed to help control appetite and metabolism and reduce fat …

Spectral Medical Announces Second Quarter and Provides Corporate Update

Spectral Medical Announces Second Quarter and Provides Corporate Update

Topline Tigris results expected to be released around mid-August 2025 TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and …

First American Uranium Announces Shares for Debt

First American Uranium Announces Shares for Debt

Vancouver, British Columbia, Aug. 08, 2025 (GLOBE NEWSWIRE) -- First American Uranium Inc. (CSE: URM) (FSE: IOR) (OTCPK: FAUMF) (the “Company”) announces that, it will enter into a debt settlement agreement for the issuance of 2,000,000 common shares in …

ParaZero’s DefendAir System Triumphs in Field Trial, Unveiling Advanced Counter-Drone Defense Solution

ParaZero’s DefendAir System Triumphs in Field Trial, Unveiling Advanced Counter-Drone Defense Solution

Kfar Saba, Israel, Aug. 08, 2025 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “company” or “ParaZero”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) …

Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant reversal of compensated cirrhosis (F4) due to MASH and …

Draganfly to Host Shareholder Update Call on August 11, 2025

Draganfly to Host Shareholder Update Call on August 11, 2025

Saskatoon, SK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO; CSE: DPRO; FSE: 3U8A), an award-winning, industry-leading developer of drone solutions and systems, announced today that it will host a shareholder update call on Monday, August …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions